Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors

A compound of formula (I)

• wherein
• A is N or C—R2, wherein
• R2 represents hydrogen, fluoro or chloro,
• R1 represents hydrogen, fluoro, chloro, methyl, ethyl or methoxy,
• and
• Z represents (C1-C4)-alkyl or (C3-C6)-cycloalkyl each of which may be substituted with hydroxy,
• or
• Z represents a heterocyclic group of the formula
• wherein * indicates the point of attachment to the pyrrolotriazine moiety,
• and
• R3 represents hydrogen or hydroxy,
• with the proviso that when R3 is hydroxy, this hydroxy is not attached to a ring carbon atom located adjacent to the ring nitrogen atom,
• or
• Z represents a thiazole group of the formula
• wherein * indicates the point of attachment to the pyrrolotriazine moiety,
• and
• R4 represents hydrogen, methyl, ethyl, amino or aminomethyl,
• or
• Z represents a group of the formula
• wherein * indicates the point of attachment to the pyrrolotriazine moiety,
• R5 represents (C3-C6)-cycloalkyl, oxetanyl, tetrahydrofuranyl or tetrahydropyranyl,
• R6 represents hydrogen or hydroxy,
• R7 represents hydrogen or hydroxy,
• with the proviso that when R7 is hydroxy, this hydroxy is not attached to a ring carbon atom located adjacent to the ring nitrogen atom,
• and
• Y is O, NH or NCH3,
• or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.